Rachel Fasiczka

This study identifies PAK6 as a modifier of LRRK2 mutations, showing it rescues ciliogenesis defects in G2019S but not R1441C mutations.

Peripheral blood-derived cells can be employed to stratify Parkinson's disease patients most likely to respond to LRRK2-related therapeutics.

This study shows that LRRK2 kinase activity causes centrosomal cohesion deficits through phosphorylated Rab10 and RILPL1 at centriolar subdistal appendages.